KRMD Stock Forecast & Price Target

KORU Medical Systems Inc. demonstrated strong financial performance in the first quarter, achieving revenue of $9.6 million, representing a year-over-year increase of 17.5%, fueled by substantial growth in both U.S. and international markets at 16% and 36%, respectively. Additionally, the company's gross margin percentage expanded by 50 basis points to 62.8%, indicating operational efficiency amid a shifting geographic mix. Management's confidence is further underscored by their decision to raise the 2025 revenue guidance by $0.5 million and plans to submit for approval two commercialized drugs related to the Freedom Infusion System later this year.

KORU Medical Systems reported an operating loss of $1.2 million, indicating ongoing financial challenges despite its focus on the high-demand market of infusion devices for chronic illnesses. The company’s performance metrics revealed operational efficiencies that did not meet expectations, reflecting a potential misalignment with industry standards. This financial strain raises concerns about the company's ability to scale effectively within a competitive medical device sector.